Merck Gerberding, Julie
Merck & Co. EVP Julie L. Gerberding Sells 38,368 Shares (MRK)
May 11th, 2015 - 0 comments - Filed Under - by Thomas Dobrow
Share on StockTwits
Merck & Co. (NYSE:MRK) EVP Julie L. Gerberding sold 38,368 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $60.99, for a total transaction of $2,340,064.32. Following the completion of the transaction, the executive vice president now directly owns 31,985 shares of the company’s stock, valued at approximately $1,950,765.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on MRK shares. Analysts at Credit Suisse reiterated a “neutral” rating and set a $62.00 price target on shares of Merck & Co. in a research note on Saturday. Analysts at Bank of America reiterated a “buy” rating and set a $65.00 price target on shares of Merck & Co. in a research note on Sunday, May 3rd. Analysts at Argus raised their price target on shares of Merck & Co. from $66.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Finally, analysts at Zacks reiterated a “hold” rating and set a $66.00 price target on shares of Merck & Co. in a research note on Friday, March 27th. Nine investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $63.38.
Shares of Merck & Co. (NYSE:MRK) traded down 1.22% during mid-day trading on Monday, hitting $60.00. The stock had a trading volume of 9,718,856 shares. Merck & Co. has a one year low of $52.49 and a one year high of $63.62. The stock’s 50-day moving average is $58. and its 200-day moving average is $58.. The company has a market cap of $170.29 billion and a P/E ratio of 14.74.
Merck & Co. (NYSE:MRK) last announced its earnings results on Tuesday, April 28th. The company reported $0.85 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.75 by $0.10. The company had revenue of $9.40 billion for the quarter, compared to the consensus estimate of $9.04 billion. During the same quarter last year, the company posted $0.88 earnings per share. Merck & Co.’s revenue was down 8.2% compared to the same quarter last year. Analysts expect that Merck & Co. will post $3.44 EPS for the current fiscal year.
Merck & Co, Inc, is a health care company. The Company delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company’s operations are principally managed on a products basis and are comprised of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments.